Obesity

India has entered the first phase of generic semaglutide approvals, with CDSCO clearing multiple formulations for obesity and diabetes, paving the way for lower-cost GLP-1 therapies

Endocrinologist explains how to build a realistic weight-loss plan that can help you lose fat without regaining it

Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term

Here's how homeostasis, hormones and obesity drugs affect why lost weight often returns faster than expected

New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken

Eating eggs has been repeatedly shown to help people feel fuller for longer and eat less at later meals, including among people who are overweight or obese

Experts say OAds, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, value moderation

Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth of the domestic pharmaceutical industry, according to Sun Pharma Managing Director Kirti Ganorkar. Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs that treat type 2 diabetes, high blood sugar, and obesity by regulating insulin production. India, known for its generic drug industry, is rapidly transforming into a major hub for the global weight management industry, amid rapid increase in obesity-led disease burden. "Improving access to GLP-1 treatments in the coming years will be a key driver for the Indian pharmaceutical industry, helping address the growing burden of lifestyle diseases such as obesity and diabetes," Ganorkar told PTI. Combined with AI-enabled digital tools for early disease detection and monitoring, and personalised medicine choices, the industry will continue to drive innovation that supports accessibility, affordability, and ..

From GLP-1 drugs and personalised cancer vaccines to longevity experiments and regenerative therapies, 2025 marked a year when scientific breakthroughs reshaped healthcare and medicine

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January, the company said in a statement Monday

As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

A new study shows how gut-produced metabolites influence insulin response and fat metabolism, opening the door to potential future treatments for obesity and type 2 diabetes

Australia has issued a safety alert on GLP-1 drugs after reviewing reports of depression and suicidal thoughts; while there is no proven causal link, regulators want users to stay alert

WHO has issued its first guidelines recommending GLP-1 drugs for long-term obesity treatment in adults, while stressing equitable access, health system readiness and lifestyle support

Metropolis Healthcare has rolled out three TruHealth GLP-1 test packages for patients preparing for or undergoing obesity treatment, as diagnostics firms move to tap the fast-growing segment

A Yale study suggests GLP-1 drugs like semaglutide slow alcohol breakdown in the liver, raising blood alcohol levels even as they reduce toxic byproducts linked to inflammation and liver damage

Pune-based Biorad Medisys is developing an implantable vagus nerve stimulation device that aims to improve insulin balance, regulate hunger, and support obesity care without drugs or chemical compound